Skip to main content
Windlas Biotech Limited logo

Windlas Biotech Limited — Investor Relations & Filings

Ticker · WINDLAS ISIN · INE0H5O01029 LEI · 3358008HGGLMCSC4GP83 BSE.NS Manufacturing
Open in API
Filings indexed 432 across all filing types
Latest filing 2026-05-18 Regulatory Filings
Country IN India
Listing BSE.NS WINDLAS

About Windlas Biotech Limited

https://www.windlasbiotech.com

Windlas Biotech Limited is a Contract Development and Manufacturing Organization (CDMO) providing integrated services from formulation development to commercial-scale production. The company specializes in manufacturing solid and liquid oral dosage forms, including tablets, capsules, sachets, and liquid orals. Its operations encompass three primary business verticals: CDMO services for domestic and multinational firms, trade generics, and over-the-counter (OTC) brands. Windlas maintains advanced research and development facilities focused on process optimization and complex generic formulations. The product portfolio covers diverse therapeutic areas such as gastrointestinal, cardiovascular, anti-diabetic, and respiratory health. The company emphasizes scalable manufacturing solutions and adherence to global quality standards to support the product lifecycles of its pharmaceutical partners.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 85% confidence The document is a formal notice under SEBI LODR Regulation 30 scheduling an upcoming conference call to discuss quarterly and full‐year earnings. It does not contain any financial results, slides, or the actual transcript but is a regulatory announcement. It does not fit Earnings Release (ER), Call Transcript (CT), Investor Presentation (IP) or any specific financial report category. Therefore, it falls under the general Regulatory Filings (RNS) category.
2026-05-18 English
Closure of Buy Back
Transaction in Own Shares Classification · 97% confidence The document is a formal regulatory announcement to stock exchanges and shareholders regarding the completion of a share buyback by Windlas Biotech Limited, including details on the extinguishment of 470,000 shares, certificates, reconciliation of capital pre‐ and post‐buyback, and confirmation letters from NSDL and the registrar. This is a transaction in the company’s own shares (share repurchase) under SEBI buyback regulations, matching the “Transaction in Own Shares” category.
2026-05-18 English
Completion of Extinguishment of 4,70,000 fully paid-up equity shares of face value of INR 5 each pursuant to buyback of Windlas Biotech Limited (the 'Company') in accordance with Regulation ....
Transaction in Own Shares Classification · 95% confidence The document is a formal announcement to stock exchanges regarding the completion of a share buyback and extinguishment of equity shares under SEBI Buyback Regulations. It provides regulatory references, confirmation letters, details of shares extinguished, and shareholding patterns pre- and post-buyback. This is not a financial report or earnings release but a corporate action notice regarding the company’s repurchase of its own shares. Under our taxonomy, this falls squarely under Transaction in Own Shares (POS).
2026-05-18 English
Post Buyback Public Advertisement pursuant to and in compliance with Buyback Regulations. The Post Buyback Public Advertisement dated May 15, 2026 has been published in the newspapers on ....
Transaction in Own Shares Classification · 90% confidence The document is a formal notice to stock exchanges about the completion of a share buyback (“Post Buyback Public Advertisement”) under SEBI Buyback Regulations. This relates directly to the company’s repurchase of its own equity shares. Under our classification, buyback or repurchase announcements fall under “Transaction in Own Shares” (POS).
2026-05-16 English
Copy of Newspaper Publication
Transaction in Own Shares Classification · 93% confidence The document is a formal submission by Windlas Biotech to BSE/NSE regarding the post-buyback public advertisement for its purchase of 470,000 equity shares under SEBI Buyback Regulations. This is an announcement and report of a share repurchase (buyback) transaction, fitting the 'Transaction in Own Shares' category.
2026-05-16 English
Windlas Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 ,inter alia, to consider and approve the audited standalone and ....
Regulatory Filings Classification · 94% confidence The document is a notice to stock exchanges under SEBI LODR Regulation 29 announcing a Board meeting date to consider and approve audited financial results and dividend. It contains no actual financial data or report, nor any management/personnel changes. It is a routine regulatory compliance announcement. Per our taxonomy, such general compliance notices that do not fit other specific categories are classified as Regulatory Filings (RNS).
2026-05-15 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.